I wouldn't be surprised if we see an RMAT or breakthrough designation granted in 2021 for advanced CHF (LVAD already has RMAT), which would be a strong sign that the FDA is going to look into accelerated approval. My only hesitation is that I am not sure if the FDA will consider class II patients as 'life-threatening' conditions... class III most definitely would, but I'll need to do a little research to answer that.
And the more I think about it... a 60% reduction in MACE and mortality in class II patients ... that's going to be very hard for a big pharma in the cardiovascular space to ignore... seeing such a strong signal of clinical benefit in reduction in MACE and mortality... I feel the question is, which big pharma is going to sign-up as a partner in 2021.
Keeping in mind that this is a randomised controlled clinical trial and will definitely be 'adequate and controlled' trial data... so it's just a matter of whether or not it meets the rest of the accelerated approval criteria...
- Forums
- ASX - By Stock
- MSB
- Ann: Mesoblast Phase 3 Chronic Heart Failure Results
Ann: Mesoblast Phase 3 Chronic Heart Failure Results, page-363
-
- There are more pages in this discussion • 660 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.31 |
Change
0.150(13.0%) |
Mkt cap ! $1.490B |
Open | High | Low | Value | Volume |
$1.15 | $1.33 | $1.15 | $25.26M | 19.99M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 161000 | $1.30 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.31 | 50400 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20000 | 1.400 |
4 | 44156 | 1.370 |
3 | 33036 | 1.360 |
4 | 40118 | 1.350 |
5 | 12690 | 1.340 |
Price($) | Vol. | No. |
---|---|---|
1.290 | 740 | 1 |
1.300 | 22000 | 4 |
1.305 | 7508 | 3 |
1.315 | 50000 | 1 |
1.320 | 68510 | 5 |
Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online